GT Biopharma Reports Third Quarter 2023 Financial Results
November 01, 2023 09:00 ET
|
GT Biopharma, Inc.
IND submission for GTB-3650, 2nd generation nanobody TriKE® for treatment of CD33+ leukemia, expected in Q4 2023Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia...
GT Biopharma Reports Second Quarter 2023 Financial Results
August 07, 2023 09:00 ET
|
GT Biopharma, Inc.
Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and initiate clinical...